Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
First Trust NYSE® Arca® Biotechnology Index Fund (FBT)
Investment Objective/Strategy - The First Trust NYSE® Arca® Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE® Arca Biotechnology Index.
There can be no assurance that the Fund's investment objectives will be achieved.
  • The NYSE® Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
  • Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.
  • The index is rebalanced quarterly based upon closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent an approximately equal weight in the index.
Fund Overview
Fund TypeBiotechnology
Investment AdvisorFirst Trust Advisors L.P.
Investor Servicing AgentBank of New York Mellon Corp
Fiscal Year-End12/31
ExchangeNYSE Arca
Inception Price$20.00
Inception NAV$20.00
Rebalance FrequencyQuarterly
Gross Expense Ratio*0.55%
Net Expense Ratio*0.55%
* As of 5/2/2022
Expenses are capped contractually at 0.60% per year, at least through April 30, 2023. Please see the Fees and Expenses of the Fund section in the fund’s prospectus for more details.
Current Fund Data (as of 6/27/2022)
Closing NAV1$139.66
Closing Market Price2$139.64
Bid/Ask Midpoint$139.62
Bid/Ask Discount0.03%
30-Day Median Bid/Ask Spread30.10%
Total Net Assets$1,312,807,109
Outstanding Shares9,400,002
Daily Volume47,523
Average 30-Day Daily Volume40,688
Closing Market Price 52-Week High/Low$176.04 / $123.32
Closing NAV 52-Week High/Low$176.03 / $123.39
Number of Holdings (excluding cash)30
NAV History (Since Inception)
Past performance is not indicative of future results.
Fund Characteristics (as of 5/31/2022)4
Maximum Market Cap.$137,150
Median Market Cap.$13,037
Minimum Market Cap.$648
Price/Cash Flow14.19
Top Holdings (as of 6/27/2022)*
Holding Percent
United Therapeutics Corporation 4.59%
Grifols, S.A. (ADR) 4.37%
Seagen Inc. 4.34%
BioMarin Pharmaceutical Inc. 3.75%
Gilead Sciences, Inc. 3.71%
Alkermes Plc 3.70%
Neurocrine Biosciences, Inc. 3.68%
Biogen Inc. 3.67%
QIAGEN N.V. 3.66%
Vertex Pharmaceuticals Incorporated 3.65%

* Excluding cash.  Holdings are subject to change.

Bid/Ask Premium/Discount (as of 6/27/2022)
  2021 Q1 2022 Q2 2022 Q3 2022
Days Traded at Premium 127 29 22 ---
Days Traded at Discount 125 33 37 ---
Hypothetical Growth of $10,000 Since Inception (as of 6/27/2022) *